炎症性肠病并发艰难梭菌感染
摘要
<正>艰难梭菌是临床最常见的机会致病菌,是抗生素相关性肠炎最主要的致病因素,几乎所有伪膜性肠炎均由艰难梭菌感染(Clostridium difficile infection,CDI)引起。近年来随着广谱抗菌药物的广泛使用,全球范围内CDI发生率不断升高,并且由于其流行菌株变异,出现B1/NAP1/027等高致病菌株,产生毒素能力增强,持续作用时间延长,导致患者病死率及复发率升高,并引起多次爆发流行,造
引文
[1]Dai C,Jiang M,Huang YH.Risk Factors Associated With Clostridium difficile Infection in Inflammatory Bowel Disease[J].JCrohns Colitis,2019,13(3):395.
[2]Balram B,Battat R,Al-Khoury A,et al.Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease:A Systematic Review and Meta-Analysis[J].J Crohns Colitis,2019,13(1):27-38.
[3]Zhang T,Lin QY,Fei JX,et al.Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease[J].Sci Rep,2016,6:29791-29798.
[4]中华医学会消化病学分会炎症性肠病学组.炎症性肠病合并机会性感染专家共识意见[J].中华消化杂志,2017,37(4):217-226.
[5]Rezapour M,Galoosian A,Liu B,et al.Clostridium difficile coinfection in inflammatory bowel disease is associated with significantly increased in-hospital mortality[J].Eur J Gastroenterol Hepatol,2018,30(9):1041-1046.
[6]Guh AY,Adkins SH,Li Q,et al.Risk Factors for CommunityAssociated Clostridium difficile Infection in Adults:A Case-Control Study[J].Open Forum Infect Dis,2017,4(4):x171-x179.
[7]Zhou YL,Xie S,Wang P,et al.Efficacy and safety of infliximab in treating patients with ulcerative colitis:experiences from a single medical center in southern China[J].J Dig Dis,2014,15(9):483-490.
[8]Zhou Y,He H,Wang P,et al.Infliximab for the treatment of Crohn’s disease:efficacy and safety in a Chinese single-center retrospective study[J].Eur J Gastroenterol Hepatol,2015,27(11):1270-1275.
[9]Wang P,Zhou Y,Wang Z,et al.Identification of Clostridium difficile ribotype 027 for the first time in Mainland China[J].Infect Control Hosp Epidemiol,2014,35(1):95-98.
[10]Singh H,Nugent Z,Yu B N,et al.Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease[J].Gastroenterology,2017,153(2):430-438.
[11]方高潮,李春艳,朱贵鹏.炎症性肠病患者艰难梭菌感染研究进展[J].大连医科大学学报,2018,40(2):176-180.
[12]Tang YM,Stone CD.Clostridium difficile infection in inflammatory bowel disease:challenges in diagnosis and treatment[J].Clin JGastroenterol,2017,10(2):112-123.
[13]秦娟秀,张灏旻,刘倩,等.艰难梭菌谷氨酸脱氢酶抗原及毒素检测试剂盒的性能评估[J].检验医学,2017,32(12):1152-1155.
[14]D’Aoust J,Battat R,Bessissow T.Management of inflammatory bowel disease with Clostridium difficile infection[J].World J Gastroenterol,2017,23(27):4986-5003.
[15]Mushtaq A.New clinical recommendations for Clostridium difficile[J].Lancet Infect Dis,2018,18(4):384.
[16]Fu N,Wong T.Clostridium difficile Infection in Patients with Inflammatory Bowel Disease[J].Curr Infect Dis Rep,2016,18(6):19-24.
[17]徐镇杰,赵渊,曹倩.粪菌移植在炎症性肠病中的疗效研究[J].国际消化病杂志,2017,37(1):47-66.
[18]向丽园,张发明.粪菌移植在艰难梭菌感染治疗中的应用[J].临床荟萃,2018,33(5):385-389.
[19]Patel K,Patel A,Hawes D,et al.Faecal microbiota transplantation:looking beyond Clostridium difficile infection at inflammatory bowel disease[J].Gastroenterol Hepatol Bed Bench,2018,11(1):1-8.
[20]Lukin DJ,Lawlor G,Hudesman DP,et al.Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile[J].Inflamm Bowel Dis,2019,25(4):775-781.
[21]Chieng M.Clostridium difficile infections in patients with inflammatory bowel disease[J].N Z Med J,2017,130(1452):68-70.
[22]Rao K,Higgins PD.Epidemiology,Diagnosis,and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease[J].Inflamm Bowel Dis,2016,22(7):1744-1754.
[2]Balram B,Battat R,Al-Khoury A,et al.Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease:A Systematic Review and Meta-Analysis[J].J Crohns Colitis,2019,13(1):27-38.
[3]Zhang T,Lin QY,Fei JX,et al.Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease[J].Sci Rep,2016,6:29791-29798.
[4]中华医学会消化病学分会炎症性肠病学组.炎症性肠病合并机会性感染专家共识意见[J].中华消化杂志,2017,37(4):217-226.
[5]Rezapour M,Galoosian A,Liu B,et al.Clostridium difficile coinfection in inflammatory bowel disease is associated with significantly increased in-hospital mortality[J].Eur J Gastroenterol Hepatol,2018,30(9):1041-1046.
[6]Guh AY,Adkins SH,Li Q,et al.Risk Factors for CommunityAssociated Clostridium difficile Infection in Adults:A Case-Control Study[J].Open Forum Infect Dis,2017,4(4):x171-x179.
[7]Zhou YL,Xie S,Wang P,et al.Efficacy and safety of infliximab in treating patients with ulcerative colitis:experiences from a single medical center in southern China[J].J Dig Dis,2014,15(9):483-490.
[8]Zhou Y,He H,Wang P,et al.Infliximab for the treatment of Crohn’s disease:efficacy and safety in a Chinese single-center retrospective study[J].Eur J Gastroenterol Hepatol,2015,27(11):1270-1275.
[9]Wang P,Zhou Y,Wang Z,et al.Identification of Clostridium difficile ribotype 027 for the first time in Mainland China[J].Infect Control Hosp Epidemiol,2014,35(1):95-98.
[10]Singh H,Nugent Z,Yu B N,et al.Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease[J].Gastroenterology,2017,153(2):430-438.
[11]方高潮,李春艳,朱贵鹏.炎症性肠病患者艰难梭菌感染研究进展[J].大连医科大学学报,2018,40(2):176-180.
[12]Tang YM,Stone CD.Clostridium difficile infection in inflammatory bowel disease:challenges in diagnosis and treatment[J].Clin JGastroenterol,2017,10(2):112-123.
[13]秦娟秀,张灏旻,刘倩,等.艰难梭菌谷氨酸脱氢酶抗原及毒素检测试剂盒的性能评估[J].检验医学,2017,32(12):1152-1155.
[14]D’Aoust J,Battat R,Bessissow T.Management of inflammatory bowel disease with Clostridium difficile infection[J].World J Gastroenterol,2017,23(27):4986-5003.
[15]Mushtaq A.New clinical recommendations for Clostridium difficile[J].Lancet Infect Dis,2018,18(4):384.
[16]Fu N,Wong T.Clostridium difficile Infection in Patients with Inflammatory Bowel Disease[J].Curr Infect Dis Rep,2016,18(6):19-24.
[17]徐镇杰,赵渊,曹倩.粪菌移植在炎症性肠病中的疗效研究[J].国际消化病杂志,2017,37(1):47-66.
[18]向丽园,张发明.粪菌移植在艰难梭菌感染治疗中的应用[J].临床荟萃,2018,33(5):385-389.
[19]Patel K,Patel A,Hawes D,et al.Faecal microbiota transplantation:looking beyond Clostridium difficile infection at inflammatory bowel disease[J].Gastroenterol Hepatol Bed Bench,2018,11(1):1-8.
[20]Lukin DJ,Lawlor G,Hudesman DP,et al.Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile[J].Inflamm Bowel Dis,2019,25(4):775-781.
[21]Chieng M.Clostridium difficile infections in patients with inflammatory bowel disease[J].N Z Med J,2017,130(1452):68-70.
[22]Rao K,Higgins PD.Epidemiology,Diagnosis,and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease[J].Inflamm Bowel Dis,2016,22(7):1744-1754.